Key statistics dashboard for Petros Pharmaceuticals, Inc. (PTPI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
Stock Data
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Valuation Multiples
| P/E Ratio | 0.00 |
| Price / Book | 0.37 |
| P/S | 0.00 |
| P/FCF | -0.06 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Cash Ratio | 1.23 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.01 |
| Cash per share | 0.07 |
| FCF per share | -0.08 |
| Tangible Book Value per share | 0.01 |
| Dividend per share | 0.00 |
Related companies: CCM · CELU · HEPA · IVF · LIXT · PETV · PKBO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of PTPI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks